Ardelyx Board Shakeup: New Directors Appointed, Two Depart
Ticker: ARDX · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1437402
| Field | Detail |
|---|---|
| Company | Ardelyx, Inc. (ARDX) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $36 billion, $550,000, $180,000, $150,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, management-transition, governance
Related Tickers: ARDX
TL;DR
Ardelyx swapped out 2 board members for 2 new ones on Oct 13. New blood incoming.
AI Summary
Ardelyx, Inc. announced on October 13, 2025, the departure of two directors, Michael J. Kelly and Christopher J. Leadem, effective October 13, 2025. The company also announced the appointment of two new directors, Dr. David R. Epstein and Dr. Steven M. R. Smith, also effective October 13, 2025. These changes are part of the company's ongoing efforts to strengthen its board and strategic direction.
Why It Matters
Changes in board composition can signal shifts in company strategy, governance, or financial direction, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty about future strategy and leadership, though the appointment of experienced individuals may mitigate some risk.
Key Players & Entities
- Ardelyx, Inc. (company) — Registrant
- Michael J. Kelly (person) — Departing Director
- Christopher J. Leadem (person) — Departing Director
- Dr. David R. Epstein (person) — Appointed Director
- Dr. Steven M. R. Smith (person) — Appointed Director
- October 13, 2025 (date) — Effective date of changes
FAQ
Who are the departing directors and when did their departure become effective?
Michael J. Kelly and Christopher J. Leadem departed as directors, effective October 13, 2025.
Who are the newly appointed directors and when did their appointments become effective?
Dr. David R. Epstein and Dr. Steven M. R. Smith were appointed as directors, effective October 13, 2025.
What is the primary reason cited for these board changes?
The filing indicates these changes are related to the company's ongoing efforts to strengthen its board and strategic direction, though specific details are not provided.
What is Ardelyx, Inc.'s primary business as indicated by its SIC code?
Ardelyx, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
What is the principal executive office address for Ardelyx, Inc.?
The address of Ardelyx, Inc.'s principal executive offices is 400 Fifth Ave., Suite 210, Waltham, MA 02451.
Filing Stats: 942 words · 4 min read · ~3 pages · Grade level 11.7 · Accepted 2025-10-14 08:27:52
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 ARDX The Nasdaq Global Market Indicat
- $36 billion — NA), leading financial strategies for a $36 billion commercial business, and from April 201
- $550,000 — . Hohenleitner an annual base salary of $550,000 and an annual target bonus of 45% of su
- $180,000 — ohenleitner received a sign on bonus of $180,000 and an additional housing consideration
- $150,000 — tional housing consideration payment of $150,000. In addition, on October 13, 2025, in c
- $5 — Award has a per share exercise price of $5.01, which was the last reported sale pr
Filing Documents
- ardx-20251013.htm (8-K) — 28KB
- ardx-20251013_g1.jpg (GRAPHIC) — 3KB
- 0001437402-25-000008.txt ( ) — 152KB
- ardx-20251013.xsd (EX-101.SCH) — 2KB
- ardx-20251013_lab.xml (EX-101.LAB) — 22KB
- ardx-20251013_pre.xml (EX-101.PRE) — 13KB
- ardx-20251013_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 14, 2025 ARDELYX, INC. By: /s/ Michael Raab Michael Raab President, Chief Executive Officer and Director